LE RDV DE L’INNOVATION PARAMEDICALE
THÉA OPEN INNOVATION and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3ready small molecule, to treat ophthalmic indications with high unmet medical need
SANOFI va acquérir Provention Bio, Inc. – une opération qui enrichit son portefeuille et lui adjoint TZIELD, premier traitement modifiant l’évolution du diabète de type 1 et retardant la phase clinique de cette maladie
PATHOQUEST and Oxford Nanopore announce the first steps in a strategic collaboration to bring the first GMP-accredited, nanopore-based biologics genetic characterisation test to market
